CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0362

Sildenafil Raw

Filed under Raw Materials. The bureau holds 124 laboratory returns for this compound from 39 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

39 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 7 10.0 9.9 10.0 24 May 2026 24 May 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 7 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 4 10.0 10.0 10.0 21 Mar 2026 2 Jun 2026
BachemCASE #VI-2026-0314 A 4 10.0 9.9 10.0 15 Mar 2026 1 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 10.0 10.0 10.0 15 Dec 2025 4 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 4 10.0 10.0 10.0 17 Feb 2026 4 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 10.0 9.9 10.0 26 Apr 2026 10 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 3 10.0 10.0 10.0 4 Nov 2025 2 May 2026
WuXi TIDESCASE #VI-2026-0335 A 3 10.0 9.9 10.0 11 Jan 2026 23 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 9.9 10.0 15 Jan 2026 24 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 4 9.9 9.9 10.0 4 Jan 2026 2 Jul 2026
Sigma-AldrichCASE #VI-2026-0829 A 4 9.9 9.9 10.0 25 Feb 2026 2 Aug 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 9.9 9.9 10.0 26 Feb 2026 25 Apr 2026
AsymchemCASE #VI-2026-0091 A 3 9.9 9.9 10.0 25 May 2026 21 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 9.9 9.9 10.0 15 Nov 2025 1 Dec 2025
QYAOBIOCASE #VI-2026-0861 A 2 9.9 9.9 10.0 4 Feb 2026 19 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 9.9 9.9 10.0 22 Jun 2026 25 Jun 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 17 Mar 2026 15 Jul 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 2 9.9 9.9 9.9 7 Jun 2026 21 Jun 2026
GenScript PeptidesCASE #VI-2026-0860 A 2 9.9 9.9 9.9 20 May 2026 22 Jul 2026
PolyPeptide GroupCASE #VI-2026-0143 A 2 9.9 9.9 10.0 22 Feb 2026 17 Aug 2026
SinoPepCASE #VI-2026-0387 A 2 9.9 9.9 9.9 26 Mar 2026 23 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 2 9.9 9.9 10.0 9 May 2026 4 Jun 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 8 9.1 8.0 10.0 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 5 8.9 7.4 10.0 23 May 2026 23 May 2026
Eros PeptidesCASE #VI-2026-0918 X 1 8.9 8.9 8.9 2 Jul 2025 2 Jul 2025
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 7 8.5 7.0 9.9 23 May 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 6 8.5 6.5 10.0 24 May 2026 24 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 8 8.4 7.7 9.4 24 May 2026 24 May 2026
Xingtai Jiachuang TechnologyCASE #VI-2026-0712 X 1 8.3 8.3 8.3 2 Apr 2025 2 Apr 2025
Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 X 1 7.9 7.9 7.9 21 May 2025 21 May 2025
Mai PeptideCASE #VI-2026-0769 X 5 7.8 6.8 10.0 2 Apr 2025 20 May 2026
Kerisite Shenzhen InternationalCASE #VI-2026-0315 X 1 7.8 7.8 7.8 7 May 2025 7 May 2025
ZhuoYan labCASE #VI-2026-0902 X 2 7.1 5.0 9.2 11 Jun 2025 26 Jan 2026
Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 X 1 6.7 6.7 6.7 25 Apr 2025 25 Apr 2025
Rayshine Peptide BiochemicalsCASE #VI-2026-0545 X 1 6.3 6.3 6.3 27 Feb 2025 27 Feb 2025
HybiopeptidesCASE #VI-2026-0305 X 1 4.0 4.0 4.0 14 Jan 2025 14 Jan 2025
Shaanxi Dideu MedichemCASE #VI-2026-0499 X 1 3.9 3.9 3.9 13 Jun 2025 13 Jun 2025
Wuhan Newtop BiotechCASE #VI-2026-0676 X 1 0.0 0.0 0.0 3 Jul 2025 3 Jul 2025

Open any subject to view the batch-level evidence for Sildenafil Raw alone.